Asian Spectator


The Times

.

LANDMARK’s ‘Destination CENTRAL’ Opens an Inspiring New Chapter for the Festive Season in Hong Kong

Heightening the Global Momentum of Louis Vuitton’s Monumental Façade and Welcoming the Arrival of “Christmas at The Gloucester Hotel”HONG KONG SAR – Media OutReach News...

TUV Rheinland Japan Accredited by South African Bureau of Stan...

COLOGNE, Germany, May 31, 2018 /PRNewswire-AsiaNet/ -- The South African Bureau of Standards (SABS) has accredited TUV Rheinland Japan's Global Technology Assessment Center in Yokohama. TUV ...

Alma, a Sisram Medical Company, Launches Alma PrimeX[TM], the ...

NURNBERG, Germany, April 13, 2021, /PRNewswire-AsiaNet/-- Alma [https://www.almalasers.com/ ], one of the global leaders of energy-based medical and aesthetics solutions, unveiled the new Al...

World's Top-10 Investment Bank Barclays selected Heaven Spring...

HONG KONG, June 21, 2018 /PRNewswire-AsiaNet/ -- After a rigorous selection process involving hundreds of world-class companies from across the Asia Pacific region, Heaven Springs Dynasty Ha...

Disney Imagination Unveiled as Name for Japan’s Inaugural Disney Cruise Ship

URAYASU, CHIBA, JAPAN - Media OutReach Newswire - 14 October 2026 - Oriental Land Co., Ltd. and ORIENTAL LAND CRUISE Co., Ltd. announced that the name of its new Disney cruise ship, to co...

Solomon Systech takes part in the special exhibition organized by the Hong Kong Museum of History and the FHKI

HONG KONG, CHINA - Media OutReach - 12 June 2020 - Solomon Systech Limited will participate in the "Striving and Transforming -- The History of Hong Kong Industry" exhibition...

The 133rd Canton Fair to Add Brand New Exhibition Sections and...

GUANGZHOU, China, March 14, 2023 /PRNewswire-AsiaNet/ The preparations of online-offline-merged 133rd China Import and Export Fair ("Cantor Fair") continue to advance. Three new exhibition s...

Medialink to join Anime Festival Asia Singapore for the first time

SINGAPORE - Media OutReach - 23 November 2023 - Medialink, the leading intellectual property (IP) management company mainly focusing on content distribution and brand licensing, announced i...

Blockpass and BuyAnyLight Announce Partnership to Bring PASS Rebate to Blockpass Users

HONG KONG, Jan 3, 2020 - (ACN Newswire) - Blockpass has announced a partnership with decentralized LED sourcing platform, BuyAnyLight. Through AdPASS, Blockpass will offer community members...

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

TOKYO, Jul 9, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, Merck's anti-PD-1 therapy, for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).The applications were based on data from the Phase 1b Study 116/KEYNOTE-524 trial, which showed clinically meaningful efficacy in the single-arm setting. These data were recently presented at the 2020 American Society of Clinical Oncology Annual Meeting and supported a Breakthrough Therapy designation granted by the FDA in July 2019. Ahead of the PDUFA action dates of Eisai's and Merck's applications, another combination therapy was approved based on a randomized controlled trial that demonstrated overall survival. Consequently, the CRL stated that the applications do not provide evidence that KEYTRUDA in combination with LENVIMA represents a meaningful advantage over available therapies for the treatment of unresectable or metastatic HCC with no prior systemic therapy for advanced disease. Since the applications for Study 116/KEYNOTE-524 no longer meet the criteria for accelerated approval, both companies plan to work with the FDA to take appropriate next steps, which include conducting a well-controlled clinical trial that demonstrates substantial evidence of effectiveness and the clinical benefit of the combination. As such, LEAP-002, the Phase 3 trial evaluating the LENVIMA plus KEYTRUDA combination as a first-line treatment for advanced HCC, is currently underway and fully enrolled. The CRL does not impact the currently approved indications for LENVIMA or for KEYTRUDA.Eisai and Merck are continuing to evaluate the LENVIMA plus KEYTRUDA combination across 13 different tumor types in 18 clinical trials including the LEAP (LEnvatinib And Pembrolizumab) clinical program.

For more information, visit https://www.eisai.com/news/2020/news202039.html.

About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:Eisai Co., Ltd.
Public Relations:
+81-(0)3-3817-5120
  
Merck & Co., Inc., Kenilworth, N.J., U.S.A. 
Media Relations
Pamela Eisele: (267) 305-3558
Michael Close: (267) 305-1211

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegalzlibraryzlibraryuk casinos not on gamstophttps://www.capitolcitycinema.org/grandpashabet girişStreamEastCrackStreamscialis 20 mg fiyathttps://elektroniksigarakeyfi.net/marka/voopoo/taraftarium24taraftarium24taraftarium24